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Abstract
A full-length dihydroorotate dehydrogenase (DHODase) sequence was cloned from a Toxoplasma gondii tachyzoite cDNA library. The
sequence was most similar to family 2 DHODases, and had a calculated molecular mass of 65.1 kDa. The full-length and two N-terminally
truncated T. gondii DHODase sequences were expressed as recombinant proteins. One of the truncated sequences complemented a
DHODase-deficient bacterial host.
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Toxoplasma gondii is a protozoan parasite responsible for
life-threatening disease in immunocompromised individuals
[1] and in the fetus [2]. Recently, Fox and Bzik [3]
demonstrated that de novo pyrimidine biosynthesis is nec-
essary for the virulence of this parasite in mice. Mutants of
T. gondii with disruptions in carbamoyl phosphate synthe-
tase II, the first enzyme of the pyrimidine biosynthetic
pathway, are able to invade normally, but are unable to
replicate [3]. Moreover, pyrimidine starvation is one of the
conditions that cause stage conversion from the tachyzoite,
the form present in active infections, to the bradyzoite,
present in latent infections [4]. These findings, together
with the observation that the parasite has a limited capacity
to salvage pyrimidines [5], place a new importance on the
enzymes of de novo pyrimidine biosynthetic pathway in T.
gondii [6]. The presence of the pathway in T. gondii has
been known since 1981 [7]. In a seminal work, Asai et al.
[8] measured specific activities of all six pyrimidine bio-
synthetic enzymes in T. gondii extracts. We recently cloned
and characterized the T. gondii aspartate transcarbamoylase,
the enzyme catalyzing the second step of the pathway [9].
Dihydroorotate dehydrogenase (DHODase) catalyzes the
fourth, and only redox step of pyrimidine biosynthesis. In
humans, this enzyme is the target of leflunomide, an
immunosuppressive drug used in treatment of rheumatoid
arthritis [10], and brequinar sodium, an antiproliferative
drug [11]. The enzyme from Plasmodium falciparum, the
parasite causing malaria, was recently evaluated as a possi-
ble drug target [12,13].
DHODases are classified into two families; family 1
enzymes are soluble, cytosolic proteins, and are found in
some bacteria and some lower eukaryotes, while family 2
DHODases are membrane associated [14]. The mammalian
DHODase is bound to the inner mitochondrial membrane,
and transfers electrons via ubiquinone to the respiratory
chain [15]. Asai et al. [8] locate the T. gondii DHODase
activity in the particulate fraction of cell extracts, and show
that it is inhibited by respiratory chain inhibitors.
To clone the DHODase, we screened 5 106 plaque
forming units of a T. gondii RH tachyzoite cDNA library
(catalog #1896, AIDS Research and Reference Reagent
Program, NIAID, NIH) using the polymerase chain reaction
(PCR) method of Israel [16] with primers, sense,
5VTCTTCTCCCAACACACCGGGT3V; and antisense,
5VCCGGCCGCTGAGACCGCCAGT3V. We isolated and
sequenced five overlapping clones containing DHODase
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sequences with inserts of f 2.5, 2.3, 1.5, 1.4, and 1.2 kb. A
full-length T. gondii DHODase sequence (1770 bp) was
constructed from two of these clones by digestion at an
internal ClaI restriction site, purification of appropriate frag-
ments, and ligation. The junction region containing the ClaI
site of the new construct was verified by sequencing.
Alignments of the full-length T. gondii DHODase
sequence with a predicted DHODase sequence fragment
Fig. 1. Alignment of the T. gondii DHODase predicted amino acid sequence with other family 2 DHODase. Seven conserved DHODase regions are underlined
in the E. coli sequence (I–VII). The locations of two alpha helices observed in crystal structures of the human DHODase are underlined and marked (a). The
corresponding sequences predicted to form alpha helices in the other DHODases are also underlined. N-terminal sequences predicted to be transmembrane
segments are shown in bold. Asterisks indicate conserved residues. Abbreviations and GenBank accession numbers are: A. thaliana, Athal, X62909; E. coli,
Ecol, X02826; H. sapiens, Hsap, M94065; P. falciparum, Pfal, L15446; R. rattus, Rrat, X80778; S. pombe, Spom, X65114; T. gondii, Tgon, AF271664.
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from a T. gondii tachyzoite library (398 bp, GenBank
BG660232) showed differences at four nucleotide posi-
tions, with an identical deduced amino acid sequence. A
DHODase fragment from a T. gondii bradyzoite library
(535 bp, GenBank AA520414, Ref. [17]) differed at one
nucleotide position, and was missing nucleotides at two
positions resulting in frame shifts.
A possible translation initiation site in the full-length
sequence was identified, and agreed with a T. gondii trans-
lation initiation consensus sequence described by Seeber
[18]. The deduced amino acid sequence had a predicted
molecular mass of 65,064 Da. An alignment [19] showed
that it contained the seven DHODase conserved regions
predicted by the BLOCKS program [20] (Fig. 1). Pairwise
alignments using the ALIGN program (http://www2.
igh.cnrs.fr/) showed that the T. gondii sequence shared
highest percent with family 2 type DHODases (Homo
sapiens, 33.6%; Arabidopsis thaliana, 33.4%; Schizosac-
charomyces pombe, 31.6%; P. falciparum, 31.7%; Escher-
ichia coli, 24.4%), and was least similar to family 1 type
DHODases (Lactococcus lactis A, 17.0%; L. lactis B,
16.2%). Additional sequences were observed between con-
served regions III and IV in both T. gondii (31 residues) and
P. falciparum (44 residues) sequences (Fig. 1).
The T. gondii DHODase sequence had a predicted iso-
electric point of 9.55 (http://www.expasy.ch/tools/
pi_tool.html). High isoelectric points are predicted for other
family 2 DHODases, and are consistent with their observed
mitochondrial locations [21,22]. The N-terminal extensions
found in family 2 enzymes, which are absent in family 1
enzymes, play a role in cellular localization. The Rattus
rattus DHODase N-terminus contains a mitochondrial tar-
geting sequence (residues 2–10) and a hydrophobic mem-
brane anchor (residues 11–18) that arrests the protein in the
inner mitochondrial membrane [23]. Potential membrane-
associated N-terminal sequences predicted by the DAS
program [24] are shown in Fig. 1. Interestingly, the N-
terminal extensions of the T. gondii and P. falciparum en-
zymes are 147 and 129 residues longer, respectively, than
that of the rat enzyme (Fig. 1).
Crystal structures of a truncated human enzyme (starting
at the sequence MATG) demonstrate that residues 30–63
form a small domain containing two alpha helices involved
in binding a brequinar analog and a leflunomide derivative
[25]. This domain forms the entrance to a hydrophobic
tunnel that leads to the ubiquinone reduction site [25].
Secondary structure predictions using PredictProtein [26]
of the corresponding sequences in the T. gondii DHODase
and the other family 2 DHODases predict the presence of
alpha helices that align with the observed helices in the
human enzyme (Fig. 1).
We cloned the full-length DHODase sequence (MAPL-
PKFD, starting at amino acid residue 1), and a truncated
sequence (MIYS-PKFD, starting at residue 181), into the
vector pBAce, under the control of the phoA promoter [27].
These two constructs contained the amino acid sequence
DRGH6 at the C-terminal end of the DHODase coding
sequence. A third truncated sequence (ALQD-PKFD, start-
ing at residue 174) was cloned into the vector P343, under
the control of the tet promoter [28]. This construct contained
an added methionine at the N-terminus, and the sequence
PGD4KH8SGS at the C-terminus of the coding sequence.
Fig. 2. Western blot showing expression of T. gondii DHODase
recombinant proteins in E. coli. Full-length and N-terminally truncated
sequences cloned into expression vectors were transformed into E. coli host
cells and grown on minimal media under inducing conditions. E. coli strain
pyr D (American Type Culture Collection, ATCC12632) was used to
express TgDHOD-MAPL and TgDHOD-MIYS recombinant proteins,
while strain BL21CodonPlus(DE3)RP (Stratagene) was used to express
TgDHOD-ALQD. Cells were sonicated in the presence of detergent (50
mM sodium phosphate, 300 mM NaCl, 0.1% Triton X-100, 1 mM
phenylmethylsulfonyl fluoride, 1 mM benzamidine), and the extracts were
centrifuged. Supernatants and washed pellets were fractionated by
denaturing gradient polyacrylamide gel electrophoresis, and transferred to
nitrocellulose. Recombinant proteins were visualized by antibodies
recognizing histidine tags (Qiagen). The expected molecular masses of
the proteins were: TgDHOD-MIYS, 46.3 kDa (Lane 1, pellet and Lane 2,
supernatant); TgDHOD-ALQD, 48.1 kDa (Lane 3, pellet and Lane 4,
supernatant); and TgDHOD-MAPL, 66.2 kDa (Lane 5, pellet and Lane 6,
supernatant). Inclusion of flavins in the growth media did not affect band
intensities. No bands were visible in host cell strains transformed with
parent vectors grown under inducing conditions.
Fig. 3. A truncated recombinant T. gondii DHODase complements a
DHODase-deficient E. coli strain. DHODase-deficient E. coli cells
(ATCC12632) were transformed with parent vectors and with constructs
expressing full-length and truncated T. gondii DHODase. Transformed cells
were grown under inducing conditions in minimal media lacking uracil, and
growth was monitored by optical density measurements at 600 nm. Cells
were transformed with (o) TgDHOD-MIYS; (q) TgDHOD-ALQD; (w)
TgDHOD-MAPL; () P343; and (j) pBAce.
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The full-length recombinant protein was present in the
insoluble fraction after sonication in the presence of deter-
gent (Fig. 2). It did not complement the DHODase deficient
pyr D strain when grown in minimal media under inducing
conditions (Fig. 3) [9,27]. Pyr D cells expressing
TgDHOD-ALQD recombinant protein grew poorly (Fig.
3), and the protein was primarily present in the pellet after
sonication and centrifugation. The shortest recombinant
protein was partially solubilized by the detergent (Fig. 2),
and complemented the DHODase-deficient strain, and thus
appeared to be catalytically active (Fig. 3). Purification of
this recombinant enzyme will allow us to begin character-
ization of the T. gondii DHODase.
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